European Companies Search Engine
EU funding (€3,913,940): Mastering skills in the training Network for attention deficit hyperactivity and autism spectrum Disorders Hor 1 Jan 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Mastering skills in the training Network for attention deficit hyperactivity and autism spectrum Disorders
Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are frequent, chronic and highly heritable neurodevelopmental disorders. Despite their societal importance, progress in understanding disease biology has been slow and no curative treatment options are available. The pan-European training network MiND aims to educate a new generation of researchers in the field of neurodevelopmental disorders, through innovation-oriented research combined with highly interdisciplinary and intersectoral international training. Research and training in MiND span state-of-the-art topics in the fields of ADHD, ASD and their yet un-investigated overlap. We combine advanced (epi-)genetics approaches with bioinformatics and develop novel cell and animal models of increasing complexity to understand pathomechanisms. Integrated with research in large human DNA-neuroimaging-cognition data sets, we push forward the understanding of the biology leading from gene to cognition and disease. Our mechanistic work is embedded in a framework exploring alternative disease definitions for ADHD and ASD across the lifespan and working towards improved treatment: we use novel cognitive assessments, we probe the microbiome for dietary interventions reducing symptoms and evaluate mindfulness training as non-pharmacological treatment options, in addition to developing new compounds for pharmacological treatment optimization and individualization. The strategic collaboration of world-leading academic groups, research-intensive commercial enterprises and patient organisations will deliver 15 young, scientifically excellent researchers which are optimally prepared for private sector and academic careers. MiND can be expected to impact patients and society by improving our understanding of disease biology, by developing novel diagnostic and treatment strategies, and by raising awareness for the necessity of research of neurodevelopmental disorders from childhood to adulthood.
Funded Companies:
| Company name | Funding amount |
| Adhd-Europe | ? |
| Braingaze SL | €123,936 |
| Eurofins Medigenomix GmbH | €62,304 |
| Fundacio Centre de Regulacio Genomica | €185,905 |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | €123,936 |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | €436,129 |
| Karolinska Institutet | €263,659 |
| King's College London | €478,254 |
| Stichting Karakter | €255,374 |
| Stichting Radboud Universiteit | €766,123 |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | €124,608 |
| Universitat de Barcelona | €247,873 |
| Universitetet I Bergen | €572,550 |
| University of Leicester | €273,288 |
Source: https://cordis.europa.eu/project/id/643051
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Adhd-Europe.